TriAct Therapeutics

TriAct Therapeutics is a privately held, late-stage clinical cancer therapeutics company focused on developing novel small molecule drugs for patients whose lives cannot be extended or improved. TriAct Therapeutics' licensed portfolio includes two clinical-stage small molecules with distinct mechanisms of action. The company’s product iniparib has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) as its lead drug for the treatment of patients with malignant glioma.